BioXell
Milan
About BioXell
BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 1 – 10
- Total funding: $81.2M
- Funding stage: M&A
- Last round: Series C (Mar 2006)
- Ticker: swx:BXLN
- Website: bioxell.com
- Phone: +39 02 21049 51
Industries & Categories
Association, Biotechnology, Education, Medical
Canonical: https://fsome.com/organization/bioxell-1862725 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.